BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bydureon: QT/QTc study started

In February, Amylin began a thorough QT (tQT) study of 300-500 pg/mL IV exenatide to support the approval of Bydureon exenatide once weekly. The company said FDA approved the design of a potentially shorter tQT study...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >